A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
Latest Information Update: 14 Nov 2024
Price :
$35 *
At a glance
- Drugs Tegoprubart (Primary) ; Antithymocyte globulin; Mycophenolate mofetil; Steroids
- Indications Renal transplant rejection
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eledon Pharmaceuticals
- 14 Aug 2024 According to an Eledon Pharmaceuticals media release, company to report interim clinical data by mid-2025.
- 03 Jun 2024 According to an Eledon Pharmaceuticals media release, data from this trial presented at the American Transplant Congress (ATC)
- 03 Jun 2024 Results published in the Eledon Pharmaceuticals Media Release